Global Idiopathic Pulmonary Fibrosis Market

Global Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type(Pirfenidone and Nintedanib), By By Distribution Channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031

Report ID: SQMIG35H2223 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 61 | Figures: 75

Global Idiopathic Pulmonary Fibrosis Market News

  • In January 2023, Daewoong Pharmaceutical and CS Pharmaceuticals entered into an agreement concerning the exclusive rights for the novel PRS inhibitor, Bersiporocin, in Greater China, encompassing mainland China, Hong Kong, Taiwan, and Macau. The deal involves CSP obtaining a license for Bersiporocin's use in treating idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic conditions, with a total value of up to USD 336 million. This includes an upfront payment and development milestone amounts of up to USD 76 million, as well as double-digit royalties on net sales.
  • In May 2022, Sandoz introduced a generic version of pirfenidone, which is designated as an AB-rated fully substitutable equivalent to Genentech's Esbriet, in the United States. The launch aims to provide patients with idiopathic pulmonary fibrosis (IPF) in the US with a more affordable treatment option.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.54 Billion in 2022 and is poised to grow from USD 3.78 Billion in 2023 to USD 6.45 Billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

The competitive landscape of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is characterized by intense research and development activities focused on developing innovative treatment options and improving patient outcomes. Pharmaceutical companies are actively engaged in introducing antifibrotic agents and targeted therapies to address the unmet medical needs of IPF patients. Additionally, healthcare providers and research institutions play a crucial role in advancing diagnostic techniques and patient care, while advocacy groups and patient organizations contribute to raising awareness about IPF and its management. The market's competitiveness is further driven by regulatory approvals, market penetration strategies, and efforts to enhance healthcare infrastructure and access to IPF treatments globally. 'Cipla Inc. (India)', 'Boehringer Ingelheim International GmbH (Germany)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'FibroGen, Inc. (US)', 'Horizon Therapeutics plc (Ireland)', 'AstraZeneca (UK)', 'Novartis AG (Switzerland)', 'GlaxoSmithKline plc (UK)', 'Genentech, Inc. (US)', 'Bristol Myers Squibb (US)', 'Biogen Inc. (US)', 'Actelion Pharmaceuticals Ltd. (Switzerland)', 'Pfizer Inc. (US)', 'Johnson & Johnson (US)', 'Sanofi (France)', 'Merck & Co., Inc. (US)', 'Gilead Sciences, Inc. (US)', 'AbbVie Inc. (US)', 'Bayer AG (Germany)', 'Amgen Inc. (US)'

A key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Market is the continuous advancement in medical research and drug development. The ongoing efforts to understand the underlying mechanisms of IPF and develop innovative therapies have resulted in the introduction of new treatment options, such as antifibrotic agents like Nintedanib and Pirfenidone. These advancements have significantly improved patient outcomes and quality of life, driving the growth of the market.

Increasing focus on the development of targeted therapies: One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the increasing focus on the development of targeted therapies. Pharmaceutical companies and researchers are actively exploring and investing in innovative treatment approaches that specifically target the underlying mechanisms and pathways responsible for IPF. This trend aims to offer more effective and personalized treatment options, potentially leading to improved patient outcomes and better disease management. Targeted therapies hold promise in addressing the complex nature of IPF and may pave the way for more tailored and precise treatments in the future.

North America dominated the Global Idiopathic Pulmonary Fibrosis (IPF) Market. The region's leading position can be attributed to well-established healthcare infrastructure, high awareness about IPF among healthcare professionals and patients, and a strong focus on research and development. North America is home to several key pharmaceutical companies actively involved in developing and marketing IPF therapies. Additionally, favorable reimbursement policies and early adoption of novel treatments contribute to the region's dominance in the IPF market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Idiopathic Pulmonary Fibrosis Market

Report ID: UCMIG35H2028 | Region: Global | Published Date: February, 2024 | Pages: 165 | Tables: Figures:

DNA Vaccine Market
Buy Now GET FREE SAMPLE
Global Idiopathic Pulmonary Fibrosis Market

Report ID: SQMIG35H2161 | Region: Global | Published Date: February, 2024 | Pages: 242 | Tables: 94 | Figures: 76

Global Tissue Diagnostics Market
Buy Now GET FREE SAMPLE
Global Idiopathic Pulmonary Fibrosis Market

Report ID: UCMIG35H2192 | Region: Global | Published Date: February, 2024 | Pages: 165 | Tables: Figures:

Cell Lysis & Disruption Market
Buy Now GET FREE SAMPLE
Global Idiopathic Pulmonary Fibrosis Market

Report ID: SQMIG35H2070 | Region: Global | Published Date: February, 2024 | Pages: 219 | Tables: 93 | Figures: 76

Global Yeast Extracts For Animal Feed Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Idiopathic Pulmonary Fibrosis Market

Product ID: SQMIG35H2223

$5,300
BUY NOW GET FREE SAMPLE